Perrigo Company plc (PRGO)
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
$14.44+1.26%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.0B
- Forward P/E
- 6.0
- Dividend yield
- 8.0%
- 52-week range
- $9.23 – $22.21
- 52-week change
- −34.23%
- EPS (trailing)
- −$12.28
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $4.3B (−2.75%)
- Net income
- −$1.4B
- Operating margin
- −26.4%
- Diluted EPS
- −$10.29
- Free cash flow
- $145M
From the company’s annual report on SEC EDGAR.
About Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr.
Headquarters: Dublin, Ireland · 8,100 employees · perrigo.com